CONTE, Pierfranco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 40.842
AS - Asia 17.512
EU - Europa 17.291
SA - Sud America 2.690
AF - Africa 378
OC - Oceania 43
Continente sconosciuto - Info sul continente non disponibili 14
Totale 78.770
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 40.377
GB - Regno Unito 5.581
SG - Singapore 5.333
CN - Cina 5.059
IT - Italia 3.381
HK - Hong Kong 2.260
BR - Brasile 2.085
VN - Vietnam 1.744
SE - Svezia 1.510
DE - Germania 1.296
UA - Ucraina 1.117
FI - Finlandia 1.100
IE - Irlanda 929
TR - Turchia 769
RU - Federazione Russa 655
FR - Francia 623
KR - Corea 462
IN - India 415
BG - Bulgaria 396
BD - Bangladesh 266
ID - Indonesia 231
AR - Argentina 196
CA - Canada 194
MX - Messico 160
IQ - Iraq 138
JP - Giappone 125
NL - Olanda 119
EC - Ecuador 98
ZA - Sudafrica 97
AE - Emirati Arabi Uniti 88
PL - Polonia 88
ES - Italia 83
PK - Pakistan 79
CO - Colombia 76
BE - Belgio 75
VE - Venezuela 61
PH - Filippine 60
CL - Cile 58
UZ - Uzbekistan 53
SA - Arabia Saudita 51
MY - Malesia 49
PY - Paraguay 48
MA - Marocco 47
LT - Lituania 42
AU - Australia 41
EG - Egitto 37
CZ - Repubblica Ceca 36
KE - Kenya 35
AT - Austria 34
NP - Nepal 33
JO - Giordania 32
TH - Thailandia 30
TN - Tunisia 29
AL - Albania 27
IR - Iran 27
AZ - Azerbaigian 25
ET - Etiopia 25
HU - Ungheria 24
TW - Taiwan 24
UY - Uruguay 24
RO - Romania 23
DZ - Algeria 22
BO - Bolivia 21
DO - Repubblica Dominicana 21
RS - Serbia 21
CH - Svizzera 20
PE - Perù 20
IL - Israele 19
JM - Giamaica 19
OM - Oman 17
PT - Portogallo 17
GR - Grecia 16
KZ - Kazakistan 16
LB - Libano 16
NG - Nigeria 16
HN - Honduras 14
SN - Senegal 14
SI - Slovenia 13
CR - Costa Rica 12
SK - Slovacchia (Repubblica Slovacca) 12
BH - Bahrain 11
CI - Costa d'Avorio 10
EU - Europa 10
KG - Kirghizistan 10
PA - Panama 10
SY - Repubblica araba siriana 10
MD - Moldavia 9
PS - Palestinian Territory 9
QA - Qatar 9
AM - Armenia 8
BW - Botswana 8
AO - Angola 7
DK - Danimarca 7
MK - Macedonia 7
NI - Nicaragua 7
TT - Trinidad e Tobago 6
BA - Bosnia-Erzegovina 5
BY - Bielorussia 5
KW - Kuwait 5
LV - Lettonia 5
Totale 78.664
Salva come PNG Salva come JPEG
Città #
Fairfield 4.172
Southend 3.802
Singapore 3.478
Ashburn 3.407
Woodbridge 3.071
Santa Clara 2.829
Houston 2.625
Jacksonville 2.286
Hong Kong 2.229
Chandler 2.036
Ann Arbor 1.736
Dearborn 1.571
Seattle 1.530
Hefei 1.525
Wilmington 1.517
Cambridge 1.376
Beijing 1.004
London 937
Dublin 924
San Jose 883
Nyköping 827
Helsinki 711
Modena 636
The Dalles 634
Los Angeles 599
Ho Chi Minh City 580
Chicago 544
Princeton 444
Seoul 429
San Diego 428
Council Bluffs 421
Hanoi 395
Sofia 381
Eugene 379
Izmir 364
New York 362
Milan 351
Lauterbourg 319
Salt Lake City 226
Shanghai 208
Moscow 203
Des Moines 202
Buffalo 193
São Paulo 192
Columbus 165
Rome 153
Jakarta 149
Dallas 144
Falls Church 142
Munich 138
Frankfurt am Main 121
Boardman 118
Elk Grove Village 116
Tampa 110
Norwalk 92
Tokyo 90
Bologna 88
Guangzhou 84
Orem 84
Da Nang 80
Haiphong 71
Brussels 67
Phoenix 67
Atlanta 64
Lancaster 63
Chennai 62
Mexico City 60
Warsaw 60
Denver 59
Naples 58
Redwood City 57
Rio de Janeiro 57
Dong Ket 54
Turin 53
Sterling 52
Belo Horizonte 51
Fremont 51
Nanjing 51
Bremen 49
Kunming 49
Porto Alegre 49
Redondo Beach 47
Falkenstein 45
Miano 44
Tashkent 44
Florence 42
Baghdad 41
Brasília 41
Brooklyn 41
Kilburn 38
Stockholm 38
Bari 37
Curitiba 37
Mumbai 37
Toronto 37
Amsterdam 36
Johannesburg 36
Montreal 36
Nuremberg 36
Verona 35
Totale 56.792
Salva come PNG Salva come JPEG
Nome #
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE 1.136
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 480
Rigenerand srl - Spin off Università di Modena e Reggio Emilia 427
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 426
MSC-delivered soluble TRAIl and paclitaxel as novel combinatory treatment for pancreatic adenocarcinoma 419
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 416
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer 414
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 406
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 405
GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. 404
Cytogenetic abnormalities and clinical features in a patient cohort affected by three or more synchronous or metachronous primitive malignancies. 399
Neoadjuvant treatment with Single – Agent Cetuximab Followed by 5-Fu, Cetuximab, and Pelvic Radiotherapy: A Phase II Study in Locally Advanced Rectal Cancer. 381
A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing 380
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 378
MSC and Tumors: Homing, Differentiation and Secretion Influence The Therapeutic Potentials 378
Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy 376
SOLUBLE TRAIL-ARMED HUMAN AD-MSC AS NOVEL CELL THERAPY APPROACH FOR PANCREATIC DUCTAL ADENOCARCINOMA 373
Isolation, characterization, and transduction of endometrial decidual tissue multipotent mesenchymal stromal/stem cells from menstrual blood 372
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 368
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 367
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 365
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 361
Le Cellule Staminali Mesenchimali: Aspetti Biologici ed Approcci Terapeutici 357
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 352
Mesenchymal progenitors aging highlights a mir-196 switch targeting HOXB7 as master regulator of proliferation and osteogenesis 347
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study 343
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 342
Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer 341
Phase I study of intraperitoneal MHC unrestricted adoptive cell therapy with TALL-104 cells in patients with peritoneal carcinosis 341
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma 338
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 335
Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.. 334
Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM 332
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 330
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer 328
Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria 328
Achievements and unmet needs in the management of advanced ovarian cancer 325
METHOD FOR PRODUCTION OF ANTI-TUMOR TRAIL PROTEIN 323
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 323
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer 322
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 318
Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas 318
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data 314
Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablation 312
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial 310
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 309
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 306
Prognostic and Predictive Value of Baseline and Posttreatment Molecular Marker Expression in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy 304
Immune characterization of breast cancer metastases: prognostic implications. 302
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. 299
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 299
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). 298
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 293
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 292
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 291
Laparoscopic approach of gastric gastrointestinal stromal tumors (GISTs): Is it still a courageous choice? Report of two cases 289
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 288
A phase I-II study of oral doxifluridine plus radiotherapy in radiosensitive tumors of the pelvic region. 287
Primary adrenal gland carcinosarcoma associated with metastatic rectal cancer: a hitherto unreported collision tumor 285
Donor Cell-Derived Osteopoiesis Originates from a Self-Renewing Stem Cell with a Limited Regenerative Contribution after Transplantation 285
Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer 280
A dose-finding study of ifosfamide by three-day continuous infusion in pretreated, advanced breast cancer patients. 280
Rare breast cancer subtypes: Histological, molecular, and clinical peculiarities 280
Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer 280
5-Fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: A randomized phase II study in metastatic colorectal cancer 278
Significance of lymph node sampling in epithelial carcinoma of the ovary. 272
Gastrointestinal stromal tumor and other primary metachronous and synchronous neoplasms as a suspicious criterion for syndromic setting 270
Prognostic value of "Dworak" tumor regression grade (TRG) after pre-operative chemo-radiotherapy in rectal cancer (RC) 270
Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of After-6 protocol 1 267
Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. 267
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 261
Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer 261
Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer 260
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 259
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. 258
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER 256
Device for cell culture 255
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. 255
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 254
Intraperitoneal versus Intravenous Cisplatin in Combination with Intravenous Cyclophosphamide and Epidoxorubicin in Optimally Cytoreduced Advanced Epithelial Ovarian Cancer: A randomized trial of the Gruppo Oncologico Nord Ovest. 252
Cardiotoxicity of Epirubicin/Paclitaxel Containing Regimens: Role of Cardiac Risk Factors 251
35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS 251
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy 249
Analysis of Bevacizumab (Bev) Therapy, Bisphosphonate Use and Osteonecrosis of the Jaw (ONJ) in >1900 Patients Treated in Two Randomized, Controlled Trials 248
A phase II study with danazol in metastatic breast cancer. 246
Biomarkers predicting clinical benefit: fact or fiction? 245
Primary Systemic Therapy in operable breast cancer: clinical data and biological fall-out 244
Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study 243
41. HER2+ EARLY BREAST CANCER: DO WE HAVE ALL THE NECESSARY ANSWERS? 242
Timing for starting second-line therapy in recurrent ovarian cancer 242
Anthracycline-based preoperative chemotherapy plus lapatinib and trastuzumab or both in HER2-positive breast cancer: Preliminary cardiac safety report of the CHER LOB trial. 241
Paclitaxel and vinorelbine in anthracycline pretreated breast cancer: a phase II study. 239
Biomarker expression and survival after primary chemotherapy for breast cancer. 239
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 238
Gemcitabine, epirubicin and paclitaxel: Pharmacokinetic and pharmacodynamic interactions in advanced breast cancer 235
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG 235
Trans-CHER-Lob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer. 235
High – dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study 235
Dose-finding study and pharmaco-kinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. 234
CHER-LOB: PREOPERATIVE CHEMOTHERAPY PLUS TRASTUZUMAB, LAPATINIB OR BOTH IN HER2-POSITIVE OPERABLE BREAST CANCER – PRELIMINARY SAFETY REPORT WITH FOCUS ON CARDIAC TOLERABILITY 231
Totale 31.609
Salva come PNG Salva come JPEG
Categoria #
all - tutte 296.241
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 296.241
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021706 0 0 0 0 0 0 0 0 0 0 396 310
2021/20226.219 88 931 783 382 147 259 445 325 648 469 962 780
2022/20236.351 741 573 316 510 659 906 77 541 1.521 83 257 167
2023/20243.774 182 248 204 229 705 349 393 705 125 114 163 357
2024/202511.504 362 159 183 872 2.139 1.812 493 761 1.480 780 1.022 1.441
2025/202622.561 1.329 1.003 2.221 3.016 3.369 2.034 2.813 1.440 2.168 2.625 543 0
Totale 79.138